Chemokine CXCL1 in serum mediates the antinociceptive effect of manual acupuncture at ST36. Issue 6 (December 2021)

• Record Type: Journal Article
• Authors: Hong, Shou-Hai; Ding, Sha-Sha; Xu, Yuan; Zhang, Kuo; Zhao, Xue; Liu, Yang-Yang; Xuan, Li-Hua; Guo, Yong-Ming; Guo, Yi
• Is Part Of: Acupuncture in medicine. Volume 39:Issue 6(2021)
• Page Start: 673
• Page End: 680
• Publication Date: 2021-12
• Subjects: complete Freund's adjuvant -- CXCL1 -- inflammatory pain -- manual acupuncture -- opioid; Acupuncture -- Periodicals; 615.892
• DOI: 10.1177/0964528421997435
• Languages: English
• ISSNs: 0964-5284

Abstract

Background: Inflammatory pain is the most common type of pain encountered clinically. The analgesic effect of acupuncture has been well-documented. Objective: The aim of this study was to investigate the involvement of chemokine CXCL1 in the serum on manual acupuncture (MA)-induced antinociception. Methods: Rats with inflammatory pain of the right hind paw were induced by intraplantar (i.pl.) administration of complete Freund's adjuvant (CFA). After wards, the CFA-injected rats were treated daily with MA at ST36 from Day 1 to Day 7, and thermal nociceptive thresholds (paw withdrawal latency; PWL) were analyzed. The concentration of CXCL1 in the serum of the rats was measured by enzyme-linked immunosorbent assay (ELISA) after the first and the last MA treatment. Subsequently, the rats were injected with two doses (5 or 10 μg) of recombinant CXCL1 through the tail vein daily from Day 1 to Day 7 or injected with two doses (6.4 or 16 μg) of anti-CXCL1 antibody using the same methods and course at 30 min before MA, and the PWLs were measured again. Finally, naloxone (500 μg, 0.1 mL) was administered by i.pl. injection into the inflamed paw 5 min before the last MA treatment or last injection of recombinant CXCL1. Results: MA significantly increased the PWLs and upregulated the expression of serum CXCL1 in the CFA-injected rats. Without acupuncture, repeated tail vein injection of recombinant CXCL1 showed an analgesic effect on CFA-induced inflammatory pain. Conversely, the neutralization of serum CXCL1 by anti-CXCL1 antibody decreased MA-induced antinociception in a time-dependent manner. Anti-CXCL1 antibody injected just once before the first MA did not affect MA-induced antinociception. The analgesic effects of MA and recombinant CXCL1 were reversed by an i.pl. injection of naloxone. Conclusion: This study indicates MA at ST36 had an analgesic effect on inflammatory pain and found a novel function of CXCL1. Increased serum CXCL1 had an antinociceptive effect on inflammatory pain induced by CFA. CXCL1 in serum appeared to be a key molecule involved in the peripheral mechanism of MA-induced antinociception. The analgesic effect of MA or recombinant CXCL1 on inflammatory pain might be mediated through a peripheral opioid pathway, which needs further investigation.